The decreased serum activity of cytosolic 5′-nucleotidase IA as a potential marker of breast cancer-associated muscle inflammation

Cytosolic 5′-nucleotidase IA (cN-IA) plays a central role in the regulation of the purine nucleotide pool in skeletal muscle, preferentially converting adenosine monophosphate to adenosine. cN-IA can act as an autoantigen in muscle diseases, including the paraneoplastic syndrome related to breast ca...

Full description

Saved in:
Bibliographic Details
Published in:Nucleosides, nucleotides & nucleic acids nucleotides & nucleic acids, 2022, Vol.41 (3), p.273-284
Main Authors: Jędrzejewska, Agata, Kutryb-Zając, Barbara, Król, Oliwia, Harasim, Gabriela, Frańczak, Marika, Jabłońska, Patrycja, Słomińska, Ewa, Smoleński, Ryszard Tomasz
Format: Article
Language:English
Subjects:
5'-Nucleotidase - metabolism
Adenosine
AMP
anti-NT5C1A autoantibody
Autoantibodies
Biomarkers
Breast cancer
Breast Neoplasms
cN-IA
Cytosolic 5′-nucleotidase 1A
Female
Humans
Inflammation
Muscles - metabolism
Myocytes
Nucleotidase
Paraneoplastic syndrome
Polymyositis
Skeletal muscle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytosolic 5′-nucleotidase IA (cN-IA) plays a central role in the regulation of the purine nucleotide pool in skeletal muscle, preferentially converting adenosine monophosphate to adenosine. cN-IA can act as an autoantigen in muscle diseases, including the paraneoplastic syndrome related to breast cancer (BC). As a result of myocyte damage, released cN-IA protein may trigger the production of anti-cN-IA antibodies (anti-NT5C1A). This work aimed to develop an effective method to measure cN-IA activity in the serum and analyze it in BC patients. Our study demonstrated that serum cN-IA activity was decreased in BC patients and we assumed it is due to the presence of specific autoantibodies. We found correlations between cN-IA activity and parameters of inflammatory muscle damage. Thus, cN-IA is worth further attention to clarify its usefulness as a biomarker of BC-associated polymyositis.
ISSN:1525-7770
1532-2335
DOI:10.1080/15257770.2021.2007396